Date:2/26/2010

the same with equal benefits for both men and for women, and for patients who had previously had a stroke and for those who had not. There were also some notable differences. Investigators found:

• The age of the patient made a difference – younger patients did better with stents, older patients did better with surgery.  For patients 69 years and younger, stenting results were superior to surgical results; the younger the patient, the larger the stenting benefit.  Conversely, for patients older than 70, surgical results were slightly better than stenting; the older the patient, the larger the surgery benefit.  
• There was no difference for debilitating or major strokes between the two groups.
• There were twice as many heart attacks in the surgical group, 2.3 percent compared to 1.1 percent in the stenting group; and more minor strokes (non-disabling strokes that largely resolved) in the stenting group, 2.7 percent versus 1.5 percent for the surgical group, occurring in the time-period surrounding the procedure.  

REMARKS FROM SCAI LEADERS

"The implications of CREST for patients at risk for stroke are significant," said

SOURCE SCAI Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program